Aphria Inc. Announces Fourth Quarter and Fiscal Year 2020 Results
Aphria reported strong financial results for Q4 and FY2020, with net revenue reaching $152.2 million, a 5% increase from Q3 and an 18% increase year-over-year. Adult-use cannabis revenue rose 27% from the previous quarter, marking the fifth consecutive quarter of growth. The company achieved an adjusted EBITDA of $8.6 million, up 49% from Q3. Cash costs per gram decreased to $0.88, down 5%. Despite a net loss of $98.8 million due to a non-cash impairment, Aphria ended the quarter with a strong cash position of $497.2 million.
- Net revenue increased 5% from prior quarter, reaching $152.2 million.
- Adult-use cannabis revenue rose 27% from prior quarter, totaling $56.7 million.
- Adjusted EBITDA from cannabis operations was $9.3 million, a 55% increase from prior quarter.
- Cash cost to produce dried cannabis per gram decreased to $0.88, down 5%.
- Net loss for Q4 was $98.8 million, a significant decline from the previous year's profit.
- Non-cash impairment of $64 million recorded due to COVID-19 impacts.
ADULT USE CANNABIS REVENUE INCREASES
Net Revenue Increases
Adjusted EBITDA from Cannabis Operations of
Cash Cost Per Gram Remained Below
LEAMINGTON, ON, July 29, 2020 /PRNewswire/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA) (Nasdaq: APHA), a leading global cannabis company, today reported its financial results for the fourth quarter and fiscal year ended May 31, 2020. All amounts are expressed in Canadian dollars, unless otherwise noted and except for per gram, kilogram, kilogram equivalents, and per share amounts.
"At Aphria, we are setting ourselves apart from the rest of the cannabis industry," said Irwin D. Simon, Chairman and Chief Executive Officer. "We have generated some of the strongest sales growth, we have one of the strongest balance sheets and cash positions, compelling consumer brands and a well-diversified global business. We are grateful for the dedication of our employees for whom our commitment to protect their safety is unwavering and remains a founding principle of our company. Our strong finish to fiscal year 2020 demonstrates that this was a transformative year for Aphria, as our net revenue increased
Key Operating Highlights - Fourth Quarter Fiscal 2020
- Gross revenue for adult-use cannabis of
$56.7 million in the fourth quarter, an increase of27% from prior quarter and the fifth consecutive quarter of growth. - Net cannabis revenue of
$53.1 million in the fourth quarter, an increase of81% from prior year quarter. - Net revenue of
$152.2 million in the fourth quarter, an increase of18% from prior year quarter and increase of5% from prior quarter. - Cash cost to produce dried cannabis per gram of
$0.88 in the fourth quarter, a decrease of5% from prior quarter. - Adjusted EBITDA of
$8.6 million in the fourth quarter, an increase of49% from the prior quarter. - Adjusted EBITDA from cannabis operations of
$9.3 million in the fourth quarter, an increase of55% from the prior quarter. - Ended fourth quarter with a strong balance sheet and liquidity, including
$497.2 million of cash and cash equivalents to fund planned Canadian and International growth. - Received its European Union Good Manufacturing Practices ("EU GMP") certification from the Malta Medicines Authority ("MMA") at the Company's subsidiary, ASG Pharma Ltd., providing the Company with the ability to ship finished dried flower and finished oil for medicinal and research use in permitted jurisdictions throughout the European Union and strengthening the Company's leadership in the region.
- Liquidated
$39 million Promissory Note from GA Opportunities Corp. for proceeds of approximately$26 million . - Reduced debt and eliminated
$6.7 million in annual cash interest costs by repurchasing an aggregate of approximately$127.5 million convertible senior notes at a25% discount to their face value, using shares issued at a31% premium to Aphria's closing market price as of May 7, 2020. - Recorded a non-cash impairment of
$64.0 million in the fourth quarter, which is largely attributable to measures taken with respect to certain of the Company's international businesses in response to the COVID-19 pandemic. - Recognized for Executive Gender Diversity by Globe and Mail's inaugural Report on Business Women Lead Here list, an annual benchmark of executive gender diversity in corporate Canada.
Key Operating Highlights - Fiscal Year 2020
- Gross revenue for adult-use cannabis of
$150.4 million in 2020, an increase of307% from 2019. - Gross cannabis revenue of
$204.7 million in 2020, an increase of129% from$89.4 million in 2019. - Net revenue of
$543.3 million in 2020, an increase of129% from$237.1 million in 2019. - Cash cost to produce dried cannabis per gram of
$1.04 in 2020, a decrease of24.1% from 2019. - Positive Adjusted EBITDA of
$17.2 million in 2020, compared to a loss of$27.7 million in 2019. - Adjusted EBITDA from cannabis operations of
$20.1 million in 2020, compared to a loss of$17.5 million in 2019.
Subsequent Events
- Aphria transferred its stock exchange listing from the New York Stock Exchange to The Nasdaq Global Select Market ("Nasdaq") on June 8, 2020. This transition did not impact the Company's primary listing on the Toronto Stock Exchange (TSX: APHA).
- Aphria, Emblem Cannabis Corporation ("Emblem"), and Aleafia Health Inc. (TSX: AH, OTC: ALEAF) amicably settled their outstanding dispute related to the termination of the parties' wholesale cannabis supply agreement on June 25, 2020, ending any and all potential claims and litigation against and between Aphria, Emblem, and Aleafia Health relating to the supply agreement.
- Filed Prospectus supplement for
$100 million (USD) At-the-Market program.
Key Financial Highlights
(In thousands of Canadian dollars)
Three months ended | Three months ended | Twelve months ended | Twelve months ended | ||
May 31, 2020 | May 31, 2019 | May 31, 2020 | May 31, 2019 | ||
Net revenue | |||||
Gross profit | |||||
Adjusted cannabis gross profit 1 | |||||
Adjusted cannabis gross margin 1 | |||||
Adjusted distribution gross profit 1 | |||||
Adjusted distribution gross margin 1 | |||||
Net income (loss) | ( | ( | ( | ||
Adjusted EBITDA 1 | ( | ||||
Q4-2020 | Q3-2020 | ||||
Distribution revenue | |||||
Net cannabis revenue | |||||
Net revenue | |||||
Kilograms (or kilogram equivalents) sold 1 | 12,557 | 14,014 | |||
Cash cost to produce dried cannabis / gram1 | |||||
"All-in" cost of goods sold / gram1 | |||||
Adjusted EBITDA from cannabis operations 1 | |||||
Adjusted EBITDA from businesses under development 1 | ( | ( | |||
Adjusted EBITDA from distribution operations 1 | |||||
Cash and cash equivalents & marketable securities | |||||
Working capital | |||||
Capital and intangible asset expenditures -wholly-owned subsidiaries1 |
Source: Aphria Inc. May 31, 2020 MD&A1 |
___________________ | |
1 | In this press release, reference is made to adjusted cannabis gross profit, adjusted cannabis gross margin, adjusted distribution gross profit, adjusted distribution gross margin, adjusted EBITDA, adjusted EBITDA from cannabis operations, adjusted EBITDA from distribution operations, adjusted EBITDA from businesses under development, gram equivalents, cash costs to produce dried cannabis per gram, "all-in" cost of sales of dried cannabis per gram and capital and intangible asset expenditures – wholly-owned subsidiaries, which are not measures of financial performance under International Financial Reporting Standards (IFRS). These metrics and measures are not recognized measures under IFRS, do not have meanings prescribed under IFRS and are as a result unlikely to be comparable to similar measures presented by other companies. These measures are provided as information complimentary to those IFRS measures by providing a further understanding of our operating results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of review of our financial information reported under IFRS. Definitions and reconciliations for all terms above can be found in the Company's Management's Discussion and Analysis for the year ended May 31, 2020, filed on SEDAR and EDGAR. |
Net revenue for the three months ended May 31, 2020 was
The average retail selling price of medical cannabis (exclusive of wholesale), before excise tax, increased to
Adjusted cannabis gross profit for the fourth quarter was
Adjusted distribution gross profit for the fourth quarter was
Selling, general, and administrative costs in the quarter increased to
Net loss for the fourth quarter of fiscal year 2020 was
Adjusted EBITDA increased by
The Company ended the fourth quarter with a strong balance sheet, including
ATM ("At-the-Market") Program Established
The Company also announced today that it has established an at-the-market equity program (the "ATM Program") under which the Company may from time to time sell an aggregate of up to US
The ATM Program will be effective until the earlier of December 22, 2021 and the issuance and sale of all of the Common Shares issuable pursuant to the ATM Program, unless terminated prior to such date by the Company or the Agents. Aphria intends to use the net proceeds from the ATM Program, if any, to fund Canadian and international expansion, working capital and general corporate purposes or to repay indebtedness. As Common Shares distributed in the ATM Program will be issued and sold at the prevailing market price at the time of the sale, or in privately negotiated transactions, prices may vary among purchasers during the period of the distribution.
Distributions of the Common Shares through the ATM Program will be made pursuant to the terms of an equity distribution agreement dated July 29, 2020 among the Company, Jefferies LLC and Canaccord Genuity LLC, as U.S. agents and Canaccord Genuity Corp. and Jefferies Securities, Inc., as Canadian agents (collectively, the "Agents").
The offering under the ATM Program will be made only pursuant to a prospectus supplement dated July 29, 2020 (the "Prospectus Supplement") to the Company's Canadian base shelf prospectus (the "Shelf Prospectus") dated November 22, 2019, and pursuant to a prospectus supplement dated July 29, 2020 (the "U.S. Prospectus Supplement") to the Company's U.S. base prospectus (the "U.S. Base Prospectus") dated November 22, 2019 and included in its registration statement on Form F-10, as amended (the "Registration Statement") (File No. 333-233426). The Registration Statement was declared effective by the United States Securities and Exchange Commission (the "SEC") on November 26, 2019. The Prospectus Supplement and the Shelf Prospectus are available on the SEDAR website maintained by the Canadian Securities Administrators at www.sedar.com, and the U.S. Prospectus Supplement, the U.S. Base Prospectus and the Registration Statement are available on EDGAR at the SEC's website at www.sec.gov. Alternatively, the agents will send copies of the Prospectus Supplement and the Shelf Prospectus, or the U.S. Prospectus Supplement and the U.S. Base Prospectus, as applicable, upon request by contacting in the U.S.: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by phone at (877) 821-7388, or by e-mail at Prospectus_Department@Jefferies.com or Canaccord Genuity LLC, Attention: Syndicate Department, 99 High Street, Suite 1200, Boston, MA 02110, Attn: Equity Syndicate Department, by telephone at (617) 371-3900 or by e-mail at prospecuts@cgf.com; or in Canada: Canaccord Genuity Corp., 161 Bay Street, Suite 3000, P.O. Box 516, Toronto, ON Canada M5J 2S1, Attention: Syndication, phone: 1-416-869-7368, email: ecm@canaccordgenuity.com or Jefferies Securities, Inc., 161 Bay Street, Suite 2700, Toronto, ON Canada M5J 2S1, Attention: Steven Latimer, phone: 416-572-2215.
This news release does not constitute an offer to sell or the solicitation of an offer to buy the Common Shares, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Conference Call
Aphria executives will host a conference call to discuss these results today at 9:00 am Eastern Time. To listen to the live call, dial (888) 231-8191 from Canada and the U.S. or (647) 427-7450 from International locations and use the passcode 3439698. A telephone replay will be available approximately two hours after the call concludes through August 29, 2020. To access the recording dial 1-855-859-2056 and use the passcode 3439698.
There will also be a simultaneous, live webcast available on the Investors section of Aphria's website at aphriainc.com. The webcast will be archived for 30 days.
We Have A Good Thing Growing
About Aphria Inc.
Aphria Inc. is a leading global cannabis company driven by an unrelenting commitment to our people, the planet, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria Inc. has been setting the standard for the low-cost production of high-quality cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. The Company's portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders' multi-generational expertise in commercial agriculture, Aphria Inc. drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion.
For more information, visit: aphriainc.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking information or forward-looking statements (together, "forward-looking statements") under applicable securities laws and are expressly qualified by this cautionary statement. Any information or statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements, including, but not limited to, statements in this news release with regards to the anticipating timing for the release of new product offerings, Aphria's market position, ability to generate consistent growth, and net revenue and adjusted EBITDA. The Company uses words such as "forecast", "future", "should", "could", "enable", "potential", "contemplate", "believe", "anticipate", "estimate", "plan", "expect", "intend", "may", "project", "will", "would" and the negative of these terms or similar expressions to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Various assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this news release. Forward-looking statements reflect management's current beliefs with respect to future events and are based on information currently available to management including based on reasonable assumptions, estimates, internal and external analysis and opinions of management considering its experience, perception of trends, current conditions and expected developments as well as other factors that management believes to be relevant as at the date such statements are made. Forward-looking statements involve significant known and unknown risks and uncertainties. Many factors could cause actual results, performance or achievement to be materially different from any future forward-looking statements. Factors that may cause such differences include, but are not limited to, risks associated with COVID-19 nationally and globally which could have a material adverse impact on Aphria's business, operations and financial results, including disruptions in cultivation and processing, supply chains and sales channels, as well as a deterioration of general economic conditions including national and/or global recessions and the response of governments to the COVID-19 pandemic in respect of the operation of retail stores; general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis or otherwise affecting Aphria's business or its consumers generally; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the cannabis industry in Canada generally; income tax and regulatory matters, including delays in the issuance of licenses; the sale and distribution of vapes; the ability of Aphria to meet its liquidity requirements to fund ongoing operations; the ability of Aphria to implement its business strategies; competition; crop failure; safety of derivative cannabis products; currency and interest rate fluctuations.
Readers are cautioned that the foregoing list is not exhaustive and should consider as other factors discussed under the heading "Risk Factors" in Aphria's most recent Annual Information Form and under the heading "Industry Trends and Risks" in Aphria's Management's Discussion and Analysis for the three and twelve months ended May 31, 2020, each available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
The schedule below is an excerpt of Aphria Inc.'s financial statements prepared on a basis consistent with IFRS for the three and twelve months ended on May 31, 2020 and filed on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. This schedule does not contain all of the information in Aphria Inc.'s financial statements that is important to you. You should read the financial statements and Management's Discussion and Analysis carefully to obtain a comprehensive understanding of Aphria Inc.'s financial statements and notes thereto under IFRS and related information.
Aphria Inc. | ||||||||
For the year ended | ||||||||
Note | 2020 | 2019 | ||||||
Cannabis revenue | $ 204,736 | $ 89,383 | ||||||
Distribution revenue | 369,214 | 157,931 | ||||||
Insurance recovery | 1,000 | -- | ||||||
Excise taxes | (31,611) | (10,204) | ||||||
Net revenue | 543,339 | 237,110 | ||||||
Production costs | 5 | 64,972 | 36,446 | |||||
Cost of cannabis purchased | 21,920 | -- | ||||||
Cost of goods purchased | 322,688 | 138,126 | ||||||
Gross profit before fair value adjustments | 133,759 | 62,538 | ||||||
Fair value adjustment on sale of inventory | 5 | 57,039 | 27,724 | |||||
Fair value adjustment on growth of biological assets | 6 | (115,255) | (40,607) | |||||
Gross profit | 191,975 | 75,421 | ||||||
Operating expenses: | ||||||||
General and administrative | 23 | 99,977 | 69,752 | |||||
Share-based compensation | 24 | 22,500 | 26,080 | |||||
Amortization | 21,747 | 14,084 | ||||||
Selling | 21,042 | 4,961 | ||||||
Marketing and promotion | 20,464 | 23,010 | ||||||
Research and development | 2,568 | 1,391 | ||||||
Impairment | 10 | 63,971 | 58,039 | |||||
Transaction costs | 5,763 | 23,259 | ||||||
258,032 | 220,576 | |||||||
Operating loss | (66,057) | (145,155) | ||||||
Finance income (expense), net | 25 | (26,347) | 6,575 | |||||
Non-operating income, net | 26 | 11,687 | 122,935 | |||||
Loss before income taxes | (80,717) | (15,645) | ||||||
Income taxes (recovery) | 15 | 3,917 | 854 | |||||
Net loss | (84,634) | (16,499) | ||||||
Other comprehensive loss | ||||||||
Other comprehensive loss | (1,150) | (119) | ||||||
Comprehensive loss | $ (85,784) | $ (16,618) | ||||||
Total comprehensive income (loss) attributable to: | ||||||||
Shareholders of Aphria Inc. | (91,961) | (14,667) | ||||||
Non-controlling interests | 22 | 6,177 | (1,951) | |||||
$ (85,784) | $ (16,618) | |||||||
Weighted average number of common shares - basic | 257,914,589 | 242,763,558 | ||||||
Weighted average number of common shares - diluted | 257,914,589 | 242,763,558 | ||||||
Loss per share - basic | 28 | $ (0.33) | $ (0.07) | |||||
Loss per share - diluted | 28 | $ (0.33) | $ (0.07) | |||||
Aphria Inc. | ||||||||
For the three months | ||||||||
2020 | 2019 | |||||||
Cannabis revenue | $ 65,461 | $ 34,306 | ||||||
Distribution revenue | 99,137 | 99,186 | ||||||
Excise taxes | (12,395) | (4,924) | ||||||
Net revenue | 152,203 | 128,568 | ||||||
Production costs | 18,917 | 13,113 | ||||||
Cost of cannabis purchased | 6,070 | -- | ||||||
Cost of goods purchased | 87,190 | 87,270 | ||||||
Gross profit before fair value adjustments | 40,026 | 28,185 | ||||||
Fair value adjustment on sale of inventory | 20,979 | 9,649 | ||||||
Fair value adjustment on growth of biological assets | (28,343) | (17,471) | ||||||
Gross profit | 47,390 | 36,007 | ||||||
Operating expenses: | ||||||||
General and administrative | 27,676 | 26,191 | ||||||
Share-based compensation | 4,855 | 3,084 | ||||||
Amortization | 5,491 | 4,528 | ||||||
Selling | 8,311 | 2,949 | ||||||
Marketing and promotion | 3,853 | 2,625 | ||||||
Research and development | 576 | 294 | ||||||
Impairment | 63,971 | -- | ||||||
Transaction costs | 1,859 | 20,329 | ||||||
116,592 | 60,000 | |||||||
Operating loss | (69,202) | (23,993) | ||||||
Finance income (expense), net | (8,732) | (2,918) | ||||||
Non-operating income, net | (23,032) | 43,124 | ||||||
Loss before income taxes | (100,966) | 16,213 | ||||||
Income taxes (recovery) | (2,123) | 453 | ||||||
Net loss | (98,843) | 15,760 | ||||||
Other comprehensive loss | ||||||||
Other comprehensive loss | 1,580 | (58) | ||||||
Comprehensive loss | $ (97,263) | $ 15,702 | ||||||
Total comprehensive income (loss) attributable to: | ||||||||
Shareholders of Aphria Inc. | (104,904) | 16,862 | ||||||
Non-controlling interests | 7,641 | (1,160) | ||||||
$ (97,263) | $ 15,702 | |||||||
Aphria Inc. | ||||||
Note | May 31, | May 31, | ||||
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | $ 497,222 | $ 550,797 | ||||
Marketable securities | -- | 20,199 | ||||
Accounts receivable | 55,796 | 25,488 | ||||
Prepaids and other current assets | 4 | 42,983 | 23,391 | |||
Inventory | 5 | 264,321 | 91,529 | |||
Biological assets | 6 | 28,341 | 18,725 | |||
Promissory notes receivable | 14 | -- | 39,200 | |||
Current portion of convertible notes receivable | 11 | 14,626 | 11,500 | |||
903,289 | 780,829 | |||||
Capital assets | 8 | 587,163 | 503,898 | |||
Intangible assets | 9 | 363,037 | 392,056 | |||
Convertible notes receivable | 11 | -- | 20,730 | |||
Interest in equity investees | 12 | -- | 9,311 | |||
Long-term investments | 13 | 27,016 | 64,922 | |||
Goodwill | 10 | 617,934 | 669,846 | |||
$ 2,498,439 | $ 2,441,592 | |||||
Liabilities | ||||||
Current liabilities | ||||||
Bank indebtedness | 16 | $ 537 | $ -- | |||
Accounts payable and accrued liabilities | 152,750 | 105,813 | ||||
Income taxes payable | 6,410 | 2,722 | ||||
Deferred revenue | 902 | 23,678 | ||||
Current portion of lease liabilities | 1,315 | -- | ||||
Current portion of long-term debt | 17 | 8,467 | 6,332 | |||
170,381 | 138,545 | |||||
Long-term liabilities | ||||||
Lease liabilities | 5,828 | -- | ||||
Long-term debt | 17 | 129,637 | 60,895 | |||
Convertible debentures | 18 | 270,783 | 421,366 | |||
Deferred tax liability | 15 | 83,468 | 87,633 | |||
660,097 | 708,439 | |||||
Shareholders' equity | ||||||
Share capital | 19 | 1,846,938 | 1,655,273 | |||
Warrants | 20 | 360 | 1,336 | |||
Share-based payment reserve | 27,721 | 36,151 | ||||
Accumulated other comprehensive loss | (1,269) | (119) | ||||
Retained earnings (deficit) | (61,215) | 12,103 | ||||
1,812,535 | 1,704,744 | |||||
Non-controlling interests | 22 | 25,807 | 28,409 | |||
1,838,342 | 1,733,153 | |||||
$ 2,498,439 | $ 2,441,592 | |||||
For the three months | For the year ended | ||||
2020 | 2019 | 2020 | 2019 | ||
Net income (loss) | $ (98,843) | $ 15,760 | $ (84,634) | $ (16,499) | |
Income taxes (recovery) | (2,123) | 453 | 3,917 | 854 | |
Finance (income) expense, net | 8,732 | 2,918 | 26,347 | (6,575) | |
Non-operating (income) loss, net | 23,032 | (43,124) | (11,687) | (122,935) | |
Amortization | 14,439 | 8,611 | 49,271 | 22,940 | |
Share-based compensation | 4,855 | 3,084 | 22,500 | 26,080 | |
Fair value adjustment on sale of inventory | 20,979 | 9,649 | 57,039 | 27,724 | |
Fair value adjustment on growth of biological assets | (28,343) | (17,471) | (115,255) | (40,607) | |
Impairment | 63,971 | -- | 63,971 | 58,039 | |
Transaction costs | 1,859 | 20,329 | 5,763 | 23,259 | |
Adjusted EBITDA from businesses under development | 2,745 | 5,514 | 13,385 | 16,240 | |
Adjusted EBITDA from distribution operations | (1,943) | (3,872) | (10,511) | (6,036) | |
Adjusted EBITDA from cannabis operations | $ 9,360 | $ 1,851 | $ 20,106 | $ (17,516) | |
For the three months | For the year ended | ||||
2020 | 2019 | 2020 | 2019 | ||
Adjusted EBITDA from cannabis operations | $ 9,360 | $ 1,851 | $ 20,106 | $ (17,516) | |
Adjusted EBITDA from businesses under development | (2,745) | (5,514) | (13,385) | (16,240) | |
Adjusted EBITDA from distribution operations | 1,943 | 3,872 | 10,511 | 6,036 | |
Adjusted EBITDA | $ 8,558 | $ 209 | $ 17,232 | $ (27,720) | |
View original content to download multimedia:http://www.prnewswire.com/news-releases/aphria-inc-announces-fourth-quarter-and-fiscal-year-2020-results-301102098.html
SOURCE Aphria Inc.
FAQ
What were Aphria's Q4 2020 earnings results?
What is Aphria's adjusted EBITDA for Q4 2020?
How did Aphria's adult-use cannabis revenue perform in Q4 2020?
What is the cash cost per gram of cannabis for Aphria?
How did Aphria's financial performance compare to the previous fiscal year?
